Published in J Exp Clin Cancer Res on May 12, 2009
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol (2010) 1.69
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist (2014) 1.61
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol (2012) 1.14
Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci (2011) 1.08
Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics (2012) 0.98
Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine. Ecancermedicalscience (2014) 0.95
New insights into the molecular pathogenesis of intrahepatic cholangiocarcinoma. J Gastroenterol (2013) 0.92
Toxicogenomic analysis of exposure to TCDD, PCB126 and PCB153: identification of genomic biomarkers of exposure to AhR ligands. BMC Genomics (2010) 0.89
Genome-wide single nucleotide polymorphism array analysis reveals recurrent genomic alterations associated with histopathologic features in intrahepatic cholangiocarcinoma. Int J Clin Exp Pathol (2014) 0.87
Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma. BMC Cancer (2015) 0.87
The expression and significance of IDH1 and p53 in osteosarcoma. J Exp Clin Cancer Res (2010) 0.86
CHD1L Is a Marker for Poor Prognosis of Hepatocellular Carcinoma after Surgical Resection. Korean J Pathol (2013) 0.83
Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget (2016) 0.82
Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Exp Mol Pathol (2015) 0.79
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. J Exp Clin Cancer Res (2015) 0.78
RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5. PLoS One (2017) 0.75
Post-transcriptional regulation of Rbm5 expression in undifferentiated H9c2 myoblasts. In Vitro Cell Dev Biol Anim (2015) 0.75
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. BMC Cancer (2016) 0.75
An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. Int J Genomics (2015) 0.75
Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics (2004) 24.18
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg (2001) 5.94
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer (2006) 3.27
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer (2006) 2.90
Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg (2001) 2.57
Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology (2005) 2.03
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology (2005) 1.78
Gallbladder carcinoma. Eur J Surg Oncol (2007) 1.65
Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol (2006) 1.60
K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res (2002) 1.57
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology (2002) 1.54
Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol (2005) 1.52
Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res (2003) 1.48
Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer (2007) 1.22
Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol (2002) 1.11
Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett (2001) 1.10
Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther (2004) 1.07
Loss of heterozygosity in dysplasia and carcinoma of the gallbladder. Mod Pathol (1999) 1.00
Genetic alterations in gallbladder carcinoma. Surg Today (2005) 0.93
Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocr Relat Cancer (2007) 0.92
Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer (1996) 0.90
Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder. J Gastroenterol (2005) 0.87
Targeting ubiquitin in cancers. Eur J Cancer (2006) 0.86
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg (2002) 8.30
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Computational identification of microRNA targets. Dev Biol (2004) 6.84
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science (2002) 5.89
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
Human ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell stage. Genes Dev (2008) 5.34
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw (2010) 5.20
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest (2010) 4.95
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
MicroRNA profiling of the murine hematopoietic system. Genome Biol (2005) 4.94
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature (2008) 4.87
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data. Genome Biol (2013) 4.67
A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood (2002) 4.59
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol (2002) 4.16
Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol (2005) 3.99
Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med (2007) 3.79
Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell (2003) 3.68
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Aire-dependent thymic development of tumor-associated regulatory T cells. Science (2013) 3.23
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst (2003) 3.15
Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg (2003) 3.14
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Directed differentiation and transplantation of human embryonic stem cell-derived motoneurons. Stem Cells (2007) 3.11
A hierarchical combination of factors shapes the genome-wide topography of yeast meiotic recombination initiation. Cell (2011) 3.08
Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol (2004) 3.08
Derivation of multipotent mesenchymal precursors from human embryonic stem cells. PLoS Med (2005) 3.04
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00
Electronic synoptic operative reporting: assessing the reliability and completeness of synoptic reports for pancreatic resection. J Am Coll Surg (2010) 2.98
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell (2006) 2.95
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
DNA methylation of the first exon is tightly linked to transcriptional silencing. PLoS One (2011) 2.80
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst (2010) 2.79
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol (2012) 2.74
Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis (2012) 2.72
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat Med (2007) 2.61
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat Genet (2013) 2.59
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol (2006) 2.58
High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg (2003) 2.56
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol (2009) 2.52
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther (2006) 2.45
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res (2007) 2.44
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas (2010) 2.43
Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol (2011) 2.42
Gastrointestinal stromal tumor: 5 years later. Cancer (2005) 2.40
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol (2002) 2.39
Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol (2012) 2.38